71 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Oncology & Haematology Audio PeerVoice

    • Science
    • 5.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists

    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists

    Visit https://www.peervoice.com/CHA860 to view the entire programme with slides. After completing “Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists”, participants will be able to: Discuss recent clinical data on the management of early-stage EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with early-stage EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

    • 18 min
    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists

    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists

    Visit https://www.peervoice.com/VDG860 to view the entire programme with slides. After completing “Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists”, participants will be able to: Discuss recent clinical data on the management of localised EGFR-mutant NSCLC; Explain best practices for mutational testing in patients with localised EGFR-mutant NSCLC; Develop strategies to improve communication and collaboration among the multidisciplinary team.

    • 26 min
    Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?

    Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?

    Visit https://www.peervoice.com/GPC860 to view the entire programme with slides. After completing “Could PSMA Be the ‘Bulls-Eye’ Target in mCRPC?”, participants will be able to: Describe the mechanism of the prostate-specific membrane antigen (PSMA) theranostic approach in metastatic castration-resistant prostate cancer (mCRPC); Recall the clinical trials for the development of PSMA radioligand therapy in mCRPC; Identify which patients may be considered candidates for 177Lu-PSMA-617 therapy.

    • 19 min
    Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy

    Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy

    Visit https://www.peervoice.com/NMW860 to view the entire programme with slides. After completing “Is It the Carrot or the Stick? Practical Strategies for Improving Adherence to Antidiabetic Therapy”, participants will be able to: Describe the cardiovascular adverse events that have been associated with use of proteasome inhibitors for treatment of multiple myeloma; Develop strategies to prevent and manage cardiovascular adverse events in patients with multiple myeloma.

    • 25 min
    Opportunistic Invasive Fungal Infections: Proactive Diagnosis of Patients at Risk

    Opportunistic Invasive Fungal Infections: Proactive Diagnosis of Patients at Risk

    Visit https://www.peervoice.com/QVJ860 to view the entire programme with slides. After completing “Opportunistic Invasive Fungal Infections: Proactive Diagnosis of Patients at Risk”, participants will be able to: Discuss the importance of increasing early recognition and diagnosis of invasive fungal infections (IFI) in patients at increased risk of infection; Identify the risk factors, clinical signs, and symptoms that would increase the index of suspicion of an IFI; Apply appropriate diagnostic and radiologic tests needed to confirm the type of IFI.

    • 23 min
    Metastatic Urothelial Carcinoma: Maintaining Stable Disease

    Metastatic Urothelial Carcinoma: Maintaining Stable Disease

    Visit https://www.peervoice.com/AZJ860 to view the entire programme with slides. After completing “Metastatic Urothelial Carcinoma: Maintaining Stable Disease”, participants will be able to: Describe the latest recommendations for first-line maintenance treatment for patients with stable metastatic urothelial carcinoma (mUC), Interpret the impact of the evidence for maintenance immunotherapy regimens in first-line mUC on treatment sequencing and long-term clinical care of the patient, Identify patients who may be eligible for first-line maintenance treatment with immunotherapy.

    • 15 min

Customer Reviews

5.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice